Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.

At Illumina, we have the opportunity to do work that transforms human health. Find genomics and biotech jobs at Illumina.

Jan 13, 2025 · Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery. To optimize analysis of the vast amounts of data involved …

Apr 3, 2023 · Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

View a complete list of Illumina sequencing and microarray products. Filter by system compatibility and other key features to narrow the list.

Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

Capture and wash best practices for Illumina RNA Prep with Enrichment (L) Tagmentation; Considerations for RNA Seq read length and coverage; Differences between the Illumina Stranded and TruSeq Stranded RNA library prep kits

Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

Jan 13, 2025 · Illumina and NVIDIA will work to make these tools accessible on the Illumina Connected Analytics platform. “Our ability to combine the power of AI with multiomics data is revolutionizing how we can understand disease,” said Steve Barnard, chief technology officer at Illumina. “By combining Illumina’s expertise in genomics data and ...